Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMS0QEP)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
SB 206553; 158942-04-2; SB-206553; Tocris-1661; CHEMBL297784; CHEBI:8977; UNII-AL4387525T; AL4387525T; SB-206,553; 1-methyl-N-pyridin-3-yl-6,7-dihydropyrrolo[2,3-f]indole-5-carboxamide; SB-206553 hydrochloride hydrate; SB206553; Lopac-S-180; AC1L1JQU; AC1Q5NRE; Lopac0_001163; GTPL189; SCHEMBL1459242; ZINC5994; DTXSID9043984; CTK8H1211; BDBM50060417; pyrrolo[2,3-f]indole-1(2h)-carboxamide, 3,5-dihydro-5-methyl-n-3-pyridinyl-; AKOS027381420; 5-Methyl-N-(3-pyridinyl)-3,5-dihydropyrrolo[2,3-f]indole-1(2H)-carboxamide; CCG-205237
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
|||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Breast
Breast adenocarcinoma
Colon
Colorectal adenocarcinoma
Kidney
Normal (Immortalized)
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
